Back to Browse Journals » Journal of Blood Medicine » Volume 3

Optimal management of pernicious anemia

Authors Andres E, Serraj K

Published Date September 2012 Volume 2012:3 Pages 97—103

DOI http://dx.doi.org/10.2147/JBM.S25620

Received 21 May 2012, Accepted 16 August 2012, Published 10 September 2012

Emmanuel Andres,1,2 Khalid Serraj3

1Department of Internal Medicine, Diabetes, and Metabolic Disorders, 2Competence Center of Autoimmune Cytopenias in Adults, University Hospital of Strasbourg, Strasbourg, France; 3Department of Internal Medicine, University Hospital of Oujda, Oujda, Morocco

Abstract: Pernicious anemia (also known as Biermer's disease) is an autoimmune atrophic gastritis, predominantly of the fundus, and is responsible for a deficiency in vitamin B12 (cobalamin) due to its malabsorption. Its prevalence is 0.1% in the general population and 1.9% in subjects over the age of 60 years. Pernicious anemia represents 20%–50% of the causes of vitamin B12 deficiency in adults. Given its polymorphism and broad spectrum of clinical manifestations, pernicious anemia is a great pretender. Its diagnosis must therefore be evoked and considered in the presence of neurological and hematological manifestations of undetermined origin. Biologically, it is characterized by the presence of anti-intrinsic factor antibodies. Treatment is based on the administration of parenteral vitamin B12, although other routes of administration (eg, oral) are currently under study. In the present update, these various aspects are discussed with special emphasis on data of interest to the clinician.

Keywords: anemia, pernicious, autoimmune diseases, gastritis, atrophic, neurologic manifestations, vitamin B12 deficiency

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Biomarkers for the differentiation of anemia and their clinical usefulness

Northrop-Clewes CA, Thurnham DI

Journal of Blood Medicine 2013, 4:11-22

Published Date: 20 March 2013

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation

Piccaluga PP, Paolini S, Bertuzzi C, De Leo A, Rosti G

Journal of Blood Medicine 2012, 3:151-156

Published Date: 29 November 2012

Treating thalassemia major-related iron overload: the role of deferiprone

Berdoukas V, Farmaki K, Carson S, Wood J, Coates T

Journal of Blood Medicine 2012, 3:119-129

Published Date: 19 October 2012

Letter to the editor

D'Alessandro V, Greco M

Journal of Blood Medicine 2012, 3:43-44

Published Date: 3 August 2012

Spontaneous resolution of macrocytic anemia: old disease revisited

Imashuku S, Kudo N, Kaneda S

Journal of Blood Medicine 2012, 3:45-47

Published Date: 2 August 2012

Treatment of anemia in chronic kidney disease: known, unknown, and both

Foley RN

Journal of Blood Medicine 2011, 2:103-112

Published Date: 1 August 2011

Deep vein thrombosis: a clinical review

Kesieme EB, Kesieme CN, Jebbin N, Irekpita E, Dongo A

Journal of Blood Medicine 2011, 2:59-69

Published Date: 29 April 2011